U.S. Online Retail and Ecommerce Stock News

NYSE:SNV
NYSE:SNVBanks

Earnings Beat and Credit Quality Gains Might Change The Case For Investing In Synovus Financial (SNV)

Synovus Financial Corp. recently reported third-quarter 2025 adjusted earnings per share of US$1.46, exceeding estimates due to higher net interest income, stronger non-interest revenues, and reduced provisions for credit losses. Management also highlighted significant improvements in credit quality, with declines in non-performing loans and charge-offs as well as expectations for continued growth in core deposits and loans in the coming quarters. We'll explore how Synovus's earnings...
NasdaqGS:CTKB
NasdaqGS:CTKBLife Sciences

Cytek Biosciences (CTKB): Evaluating Valuation After TIME's Growth Leaders 2026 Recognition

Cytek Biosciences (CTKB) is catching fresh attention after being named to TIME’s 2026 list of America’s Growth Leaders, a recognition that highlights the company’s momentum and strengths in cell analysis technology. See our latest analysis for Cytek Biosciences. After a standout mention on TIME's Growth Leaders list, Cytek’s share price has surged, up 39% in the last month and 35% over the past quarter, as excitement builds around its innovative tech and recognition is fueling fresh momentum...
NYSE:PSFE
NYSE:PSFEDiversified Financial

Paysafe (PSFE): Has the Recent Earnings Reset Changed the Value Story?

Paysafe (NYSE:PSFE) shares have come under fresh scrutiny after the company announced higher net losses for the third quarter and trimmed its full-year revenue and earnings guidance. Several analysts responded by lowering their outlooks in response to concerns over ongoing risks. See our latest analysis for Paysafe. This year’s momentum around Paysafe has turned sharply negative, with the stock’s latest price at $6.98 and a year-to-date share price return of -59.7%. Even with some highlights,...
NasdaqGS:AVXL
NasdaqGS:AVXLBiotechs

Why Anavex Life Sciences (AVXL) Is Down After an EMA Setback for Its Alzheimer’s Drug Application

Anavex Life Sciences recently reported that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative trend vote on the company’s Marketing Authorisation Application for blarcamesine, an investigational oral treatment for early Alzheimer’s disease. This outcome prompts Anavex to seek a re-examination and submit additional biomarker data, while maintaining regulatory dialogue with both European and U.S. health authorities. We'll explore how this...